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Abstract
OBJECTIVE: To review the pharmacodynamics and pharmacotherapeutic use of intravenous
(IV) artesunate for the treatment of severe malaria.
DATA SOURCES: Literature retrieval was accessed through PubMed (1999 to March 2010) and
Medline (1996 to March 2010) and the Centers for Disease Control and Prevention (CDC) using
the search terms artemisinin, artesunate, malaria, and severe malaria. In addition, reference
citations from publications identified were reviewed.
STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the
data sources were reviewed. Focus was placed on postmarketing trials examining the safety and
efficacy of artesunate in comparison to other regimens.
DATA SYNTHESIS: The treatment of severe malaria requires prompt, safe, and effective
intravenous antimalarials. Many oral and intravenous agents are available worldwide for the
treatment of malaria; however, quinindine has been the only option for parenteral therapy in the
US. Furthermore, lack of this product’s availability and an adverse safety profile has created a
treatment option gap. Recently, IV artesunate was approved by the FDA for investigational drug
use and distribution by the CDC. Three major studies regarding the use of IV artesunate are
reviewed in addition to the World Health Organization’s malaria treatment guidelines. While
there are no published head-to-head trials of IV artesunate versus IV quinidine for severe
malaria, several international studies comparing intravenous quinine and artesunate conclude that
artesunate has the highest treatment success with lower adverse events. In addition, other
literature is reviewed regarding counterfeit and other issues associated with artesunate.
CONCLUSION: Artesunate, a new antimalarial currently available through the CDC, appears to
be highly effective, better tolerated than quinidine, and not hampered by accessibility issues. If it
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were to be FDA approved and commercially available, it would be the preferred agent for the
treatment of severe malaria in the United States
KEY WORDS: artesunate, artemisinin, severe malaria
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Introduction
Malaria, caused by a protozoan transmitted by Anopheles mosquitoes, is endemic in over
100 countries, which are visited by more than 125 million international travelers, 64 million of
them from the U.S., each year.1 Nearly 250 million cases and 1 million deaths are reported
annually around the world.2 In the United States, approximately 1,500 cases of malaria are
imported each year, of which nearly two-thirds are caused by Plasmodium falciparum (85% of
cases from Africa).3 While mortality was low in the 2007 CDC surveillance report, at least 57
people were classified as having severe malaria that year.
A malaria infection is categorized as severe when at least one of the following
complications is present: hypotension, hypoglycemia, severe anemia, hyperparasitemia (>5% or
250,000 parasites per microliter of blood), hemoglobinuria, jaundice, acidosis, hyperthermia,
neurologic involvement such as a decreased level of consciousness or seizures, acute respiratory
distress syndrome, or renal failure. Parasitemia is defined as the percentage of red blood cells
that are infected on a standard thin blood smear. A review of malaria among U.S. travelers from
1963 to 2001 found that 185 persons with imported malaria died.4 Common contributors to
death included lack of malaria chemoprophylaxis, delay in seeking care, misdiagnosis, and
incorrect antimalarial regimens (i.e., therapy that was inappropriate for the species or region of
acquisition). Severe malaria is a medical emergency requiring immediate treatment to prevent
death. Uncomplicated malaria includes those who are symptomatic, but do not have severe
disease or evidence of vital organ system dysfunction. The goal of the treatment of
uncomplicated malaria is to eradicate the infection whereas the goal of the treatment of severe
malaria is to first prevent death.

Page 5 of 28

In the United States, intravenous (IV) quinidine gluconate (a diastereomer of quinine) is
the only Food and Drug Administration (FDA)-approved, commercially available medicine for
the treatment of severe malaria. However, it is in short supply nationally and its use is associated
with cardiotoxicity and other adverse reactions such as cinchonism (i.e. tinnitus, headache,
dizziness, diarrhea, and abdominal discomfort), and hypoglycemia. 5, 6,7
The artemisinin class of antimalarials represents the newest class of medications for the
treatment of uncomplicated and severe malaria. However, the only commercially available
artemisinin in the United States is oral artemether (in combination with lumefantrine, brand
name Coartem®), which was FDA-approved in April 2009 and is indicated for the treatment of
uncomplicated falciparum malaria. On June 21, 2007, the FDA approved an investigational new
drug (IND) protocol using IV artesunate for the treatment of severe malaria in the United States.
The drug is made available by the U.S. Centers for Disease Control and Prevention (CDC) and
produced by the Walter Reed Army Institute of Research. The World Health Organization
(WHO) as well as the United Kingdom and Canada recommend artesunate over quinidine for
treatment of severe malaria.8-10
Methods for Selection and Assessment of Literature
A search of PubMed (1999 to March 2010) and Medline (1996 to March 2010) was
performed using the key words artesunate, artemisinin, malaria, and severe malaria to identify
clinical trials and review articles of artesunate in the English language. Focus was placed on
postmarketing trials of the safety and efficacy of artesunate compared with other regimens, most
notably quinine, for the treatment of severe malaria. The references of the identified articles were
reviewed for additional citations. In addition, the CDC’s website (http://www.cdc.gov) was
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searched for information on the use of artesunate in the United States and to obtain its IND
protocol.
Chemistry and Pharmacology
More than 1500 years ago in China, extracts of qinghao (sweet wormwood, Artemisia
annua L.) were discovered to have antipyretic properties; subsequent analysis found that a
component of this extract, qinghaosu, had antimalarial activity. Qinghaosu, better known today
as artemisinin, is the basis for the newest class of antimalarial medications. Artemisinin is a
sesquiterpene lactone with an internal peroxide bridge (Figure 1).11 One potential mechanism of
action of artemisinins involves that endoperoxide bridge. It has been postulated that when
artemisinins react with Fe2+ in the body, the peroxide bridge is cleaved producing oxygencentered free radicals that are subsequently converted to carbon-centered free radicals, which
may have direct antiparasitic activity.11,12 Evidence also suggests anti-parasitic activity may be
due to the inhibition of sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA) of P.
falciparum.13
Derivatives of artemisinin—including arteether, artelinate, artemether, artesunate
(artesunic acid), and dihydroartemisinin—differ from the parent artemisinin by substituted
groups at position 10 (Figure 1).11 A unique feature of this class of drugs is the ability to kill all
erythrocytic stages of the malaria parasite, including gametocytes involved in the transmission of
malaria from person to person.5 In addition, artemisinins inhibit parasite metabolism faster than
other antimalarials and enhance spleen clearance of infected erythrocytes through reduced
cytoadherence.11
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Pharmacokinetics and Pharmacodynamics of IV Artesunate
Artesunte for intravenous administration is supplied in vials containing 110mg of the
medication as a sterile dry-filled powder. It is to be reconstituted with 11ml of a sodium
phosphate diluent which yields a net concentration of 10mg/ml. The resultant solution should be
gently mixed for five to six minutes and must be administered within one hour. Following
reconstitution, it should be pushed intravenously over one to two minutes through a 0.8 micron
hydrophilic polyethersulfone filter.7
The dosing of IV artesunate has evolved with increased experience with the drug. The
previously recommended dose of 1.2 mg/kg/day was empirically derived from the absolute
bioavailability of oral artesunate (F=61%). 14-16 Over time, the dose of IV artesunate for the
treatment of severe malaria was increased from the previously recommended empiric dose to 2.4
mg/kg to prevent underdosing in critically ill patients with malaria.15-17 The 2.4 mg/kg per dose
is now considered the standard of practice. After three days of therapy with IV artesunate, a
majority of patients will have recovered sufficiently to tolerate and be switched to oral
medications; however, for those that cannot, IV artesunate can be continued for another four
days or the patient may be switched to IV doxycycline or IV clindamycin.7
Artesunate is a prodrug and is rapidly hydrolyzed to dihydroartemisinin (DHA), the
active constituent and source of the medications antiparasitic activity, directly following
administration. DHA is then subsequently metabolized by CYP2B6, CYP2C19, and CYP3A4
enzymes to inactive metabolites.11,16,18 Furthermore, IV artesunate does not need to be dose
adjusted in patients with either renal or hepatic insufficiency.5 Artemisinins, including
artesunate, are considered to be the most important antimalarial agents worldwide because of
their potency (can reduce parasitemia by 10,000 fold in each asexual lifecycle), rapid
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antiparasitic activity and resolution of symptoms, limited resistance in malaria parasites, and
good tolerability.5,8,11 However, their use as monotherapy is limited by extremely short half-lives
of approximately 45 minutes.11 Short courses of monotherapy result in unacceptably high rates of
recrudescence and raise concerns for drug resistance. Thus, intravenous artesunate, as approved
for use in the United States, should be used sequentially with a second oral medication such as
atovaquone-proguanil, doxycycline, clindamycin, or mefloquine after three days of use. Oral
medications should be initiated on the last day of artesunate therapy, at least four hours after the
last infusion.7
In one pharmacokinetic study, Newton et al. found that after administration of 2.4 mg/kg
of IV artesunate to 11 adult patients with severe malaria, the median plasma concentration at
time zero was 338 (range 124 to 2557) nmol/L, the median half-life of artesunate was 13.2
(range 4.8 to 36.6) minutes, and the median time to undetectable drug was 30 (range 15 to 120)
minutes.16 In this same study, the median Cmax of DHA was 6292 (range 146 to 1646) ng/mL,
which was reached within 15 minutes by all patients, and the median half-life of DHA was 20.4
(range 8.4 to 52.2) minutes. Median DHA clearance was 5.6 (range 2.9 to 16.6) L/kg/hr. One
patient with severe malaria died in this study with only median values for all pharmacokinetic
parameters.16
Clinical Studies and Guidelines
Clinical studies have evaluated the safety and efficacy of artesunate in comparison to
quinine in patients with severe malaria. Results from selected trials are summarized below as
well as in Table 1.19-23 A brief summary of the WHO malaria treatment guidelines as they pertain
to artesunate are also included.
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Newton et al. compared the safety and efficacy of IV quinine to IV artesunate in a
randomized, open-labeled study involving 113 persons ≥ 15 years of age in Western Thailand
with slide confirmed P. falciparum parasitemia of > 0.1% and that were determined to have
severe malaria.21 42% of all patients in this study had a parasitemia level of > 10%. Pregnant
women, those with contraindications to study medications, and those who received artesunate,
quinine, or mefloquine in the previous 24 hours were excluded from the study. Patients in the
artesunate group (n=59) received 2.4 mg/kg on entry, 1.2 mg/kg 12 hours later, and then 1.2
mg/kg/day. Patients in the quinine group (n=54) received 20 mg/kg of medication administered
IV over four hours followed by 10mg infused over two hours and given three times daily. There
was no mention of specifically when either artesunate or quinine was first initiated (i.e. on
hospital admission or on study enrollment) by the investigators. This may have lead to delays in
treatment thus impacting overall mortality rates in this study. However, when patients were able
to tolerate oral medications, they were switched accordingly to either oral artesunate or oral
quinine.
Overall, 17% of the patients died in this study. Death was attributable to pulmonary
edema/acute respiratory distress syndrome, cardiorespiratory arrest, hypotension, oliguria, and/or
gastrointestinal tract bleeding. Seven patients (12%) in the artesunate group and 12 patients
(22%) in the quinine group died, RR=0.53 (0.23-1.26), p=0.22. Median time to death was also
shorter in the quinine group (21 hours) than in the artesunate group (48 hours), p=0.02. In
addition, the mean time for parasitic clearance in the quinine group (76 hours) was longer than in
the artesunate group (62.5 hours), p=0.019. The investigators concluded that artesunate is at least
as effective as quinine in the treatment of severe malaria and is likely safer, as fewer patients
receiving artesunate developed hypoglycemia compared with those receiving quinine (10.2%
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versus 28%, p=0.028). Despite these initial findings, however, larger trials were deemed to be
needed to evaluate the benefit of artesunate in reducing mortality.
The South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT; Dondorp, et al)
compared IV artesunate to IV quinine in a randomized, open-labeled, multicentered trial among
1,461 patients in Bangladesh, India, Indonesia, and Myanmar (Burma) in perhaps the largest and
most definitive trial to date.23 Patients were enrolled if they were older than two years of age, had
a positive blood antigen test for Plasmodium falciparum histadine rich protein 2 (HRP2), and
had a diagnosis of severe P. falciparum malaria by the attending physician. Individuals were
excluded if they had received a full treatment with quinine or an artemisinin derivative for more
than 24 hours before admission or had a known allergy to a study medication. Patients
randomized to the artesunate group (n=730) received 2.4 mg/kg on admission and then again at
12 and 24 hours followed by daily administration of IV artesunate until oral therapy could be
tolerated. Those receiving quinine (n=731) received 20 mg/kg infused over 4 hours followed by
10 mg/kg infused over 2 to 8 hours 3 times daily until oral therapy could be started. The study’s
primary endpoint was mortality from severe malaria.
Overall, 19% of the patients in this trial died; mortality was significantly lower in the
artesunate group (15%) than in the quinine group (22%), OR=0.60 (0.45 to 0.79), p=0.0002.
Reduction in mortality occurred primarily after the first 24 to 48 hours after treatment began
which indicates that prompt treatment of severe malaria is vitally important. There was a
statistically significant reduction in mortality associated with artesunate in adults (16% versus
24%, P < 0.0005) but not in children (5% versus 11%, P=0.15). The small number of children
enrolled (n=202) may have contributed to this study’s inability to detect a statistically significant
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difference; however, this does not rule out a potentially clinically significant effect of artesunate
when used in children.
Patients with parasitemia > 10% on admission (defined as hyperparasitemia by the study
investigators) had a greater reduction in mortality with artesunate as compared to nonhyperparasitemic patients, OR=0.34 (0.17 to 0.69), p=0.001. The calculated number needed to
treat (NNT) to save one life with artesunate ranged from 11.1 to 20.2. Among surviving patients,
the incidence of hypoglycemia was greater in the quinine group (3%) than in the artesunate
group (<1%), p=0.009. Based on these results, the investigators suggest that artesunate should be
the drug of choice to treat severe malaria in adults. A statistically significant effect was not
observed in children and therefore the same conclusion could not be reached as in adults;
however, the drug did show benefit in this population.
In a 2007 Cochrane review, Jones et al. conducted a systematic literature review to
evaluate the use of artesunate versus quinine for the treatment of severe malaria.24 Six
randomized controlled trials were identified (Anh 1989, Hien 1992, Anh 1995, Phuong 1997,
Newton 2003, and Dondorp 2005) for a total enrollment of 1,938 individuals (1,664 adults and
274 children) with severe malaria as determined by study investigators. Phuong, et al. were the
only investigators to enroll only children; they randomized treatment to either artemisinin
suppositories, IM artesunate, or IV quinine.22 All six studies were conducted in Asia
(Bangladesh, Myanmar, India, Indonesia, Thailand, and Vietnam); the primary outcome measure
was mortality from severe malaria. From their review of these trials, the authors concluded that
artesunate was superior to quinine in reducing death from severe malaria (RR 0.62, 0.51-0.75).
Furthermore, the authors stated that artesunate should be the drug of choice for the treatment of
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severe malaria in adults; however, the same conclusion could not be reached for children as a
significant benefit with artesunate treatment could not be found similar to the SEAQUMAT trial.
According to the 2005 WHO malaria treatment guidelines, IV artesunate is the drug of
choice for the treatment of severe malaria in adults. However, there is insufficient data to
recommend the use of artesunate over other agents for the treatment of severe malaria in
children.8 This recommendation is based largely on the results of SEAQUAMAT which showed
a statistically significant treatment benefit with artesunate in adults but not in children.23
Adverse Reactions
Artemisinin derivatives, including artesunate, have been used to treat cases of malaria
worldwide with few reported severe adverse reactions. Compared with quinine and quinidine,
they are considered less toxic and have fewer side effects.7,25,26 While formal human toxicity data
are limited, evidence and surveillance data suggest that this medication class is safe to use in
adults and children.7 Furthermore, reports of severe allergic reactions are rare, although a small
number of patients (approximate risk of 1 in 3,000 patients) have had a urticarial rash with
additional symptoms such as hypotension, pruritis, edema, dyspnea.21,27 Common adverse
reactions to IV artesunate include dizziness, nausea, vomiting, anorexia, diarrhea, transient
reticulocytopenia, and a bitter or metallic taste during infusion; however, discerning between
adverse effects and symptoms from severe malaria may be difficult.7,21,25,28 At doses of 6mg/kg,
elevations in ALT and BUN have been observed and at doses of 15mg/kg, bradycardia may
occur.7
Precautions and Contraindications
Intravenous artesunate is considered to be widely tolerated by almost all patients at
recommended dosages.7 Concerns have been raised however regarding its potential to interfere
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with normal cardiac conduction since high intramuscular doses of other artemisinin derivates
(e.g. artemether and artemotil) have caused QT prolongation in animal models which raise the
concern of a class effect.
To evaluate the effect intravenous artesunate may have on cardiac conduction, Maude et
al. studied the electrocardiograms (EKGs) of patients ≥ 16 years old with severe malaria on
admission that were given intravenous artesunate and then again after the last dose of artesunate.
Patients were initially given IV artesunate at 2.4 mg/kg, followed by 2.4 mg/kg at 12 and 24
hours and then every 24 hours thereafter. EKG’s were recorded at time 0 (prior to artesunate
therapy) and then at 10, 30, 60, 120, and 240 minutes following administration of artesunate.
Blood pressure, heart rate, and temperature were also measured at these time points. The primary
outcome in this study was a change in QTc before and after artesunate with a significant change
in QTc being defined as > 500ms in an individual patient or a mean increase of > 25% in all
patients. No significant change in the mean QTc was observed nor did any patient have an
increase in QTc of > 25% above baseline. The investigators therefore concluded that intravenous
artesunate does not have a consistent cardiovascular or electrocardiographic effect when
administered.29
Artemisinin-induced neurotoxicity in humans has also been a concern because this side
effect has been observed in animal models when either very high doses (range 25 to 250
mg/kg/day) or when the lipophilic artemisinins (e.g, artemether and arteether) have been
administered. Such neurotoxic effects in laboratory animals may include auditory dysfunction,
ataxia, hypersalivation, as well as deleterious effects on the brainstem.7,25 It is important to note
that these or other CNS related side effects have not been directly associated with any
artemisinin, including artesunate, in humans at currently recommended doses. In addition, severe
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malaria itself can cause deficits in neurological functioning; therefore, differentiating between
symptoms of severe malaria and adverse drug reactions from treatment may be difficult. The
only known contraindication to artesunate is a known allergic or anaphylaxic reaction to the
medication.7 While there is little known about drug-drug interactions with IV artesunate, its short
half-life of less than two hours suggests this is not a significant concern.
Special Populations – Pediatrics
Children, particularly those residing in areas of high malaria transmission (e.g. Africa),
are at risk for developing severe malaria due to their limited immunity from previous exposures.
Despite positive findings from SEAQUAMAT in the adult population, the efficacy of artesunate
for the treatment of severe malaria in the pediatric population remains to be clearly established.
In SEAQUAMAT, 202 children (age < 15 years) were enrolled. While fewer died in the
artesunate group than in the quinine group (5 vs. 11% respectively), the results were not
statistically significant. Therefore, the authors could not conclude that artesunate was superior to
quinine; however, the medication did appear to be effective in the pediatric population for the
treatment of severe malaria as mortality was less in the artesunate group. It is important to note
that the presentation of malaria may also differ in children than in adults and childhood mortality
from malaria tends to occur within the first 24 hours after treatment initiation giving
antimalarials less time to work.23 Large-scale studies, similar to SEAQUAMAT, are therefore
needed to evaluate the use and efficacy of IV artesunate in the pediatric population. One such
study, AQUAMAT (an open labeled randomized comparison of injectable artesunate and quinine
in children with severe falciparum malaria in Africa), is currently underway. Artesunate is
available to children in the U.S. under IND protocol despite the lack of statistical evidence
demonstrating superiority over quinine.
Page 15 of 28

Special Populations – Pregnancy
In pregnant animals given IV artesunate, fetal resorption and abortion, cardiac
malformations, and skeletal defects have been observed. There is a thus theoretical risk of
artesunate causing teratogenicity in humans because of the medication’s ability to cross the
placenta. However, in trials conducted in Thailand, the Gambia, and Sudan that primarily
involved women in their second or third trimester of pregnancy (n=2045) who were given either
artesunate alone or in combination with other antimalarials found that birth weight, duration of
gestation, placenta weight, and congenital abnormality rates were not statistically different than
in the community.7 While the number of pregnant women treated with artesunate remains
relatively low, continuous observations will need to be made to better assess the risk of
artesunate teratogenicity.
Currently, the WHO recommends the use of artesunate over quinine in pregnancy in the
second and third trimesters due to higher rates of mortality versus non-pregnant adults in
addition to the risk for fetal mortality and premature birth.8 Hypoglycemia is also a common
complication during these stages of pregnancy and quinine use may further cause hypoglycemia
to occur. In the first trimester, the severity of hypoglycemia is not as great and the risks of using
artemisinin derivatives appear to be greater; therefore, the risk of using artesunate during the first
trimester of pregnancy should be weighed against the potential for complications from severe
malaria. During the first trimester, the WHO advocates the use of either artesunate or quinine.8
Therapeutic Issues and Controversies
Access to IV Artesunate in the United States
While IV artesunate itself is not currently approved by the FDA, it is available in the
United States through the CDC under IND protocol #76,725 in collaboration with the Walter
Page 16 of 28

Reed Army Institute of Research. Under this IND, IV artesunate is available only for the
treatment of patients with severe malaria (see table 2 for eligibility criteria).7
Artesunate is available from the CDC (see www.cdc.gov/malaria for details). Depending
on the time of day and distance to the treatment facility, artesunate is sent by the fastest method
available including ground courier or commercial flight. Once received, artesunate should be
administered as soon as possible. If during therapy a serious adverse drug reaction is
experienced, it must be reported to the CDC within 24 hours by telephone and a Serious Adverse
Event Report Form must also be submitted to the CDC within 10 days.7 Currently,
approximately 70 patients have been successfully treated with IV artesunate in the United States
since August 2007 (CDC unpublished data).
Resistance to Artesunate
The use of IV artesunate as monotherapy for severe malaria is limited as discussed
previously in the pharmacokinetics and pharmacodynamics section. While resistance to
artesunate and to other artemisinin derivates appears to be minimal at present, two recent reports
of P. falciparum resistance in Western Cambodia raise concern that resistance to this important
class of medication may occur in the future.30,31
Counterfeit Medications
Although any type of medicine may be counterfeited, artesunate has been
disproportionately targeted internationally due to the relatively higher retail price and high
demand. 32,33 A counterfeit medicine is one that is deliberately and fraudulently mislabeled with
respect to identity and/or source. Counterfeit products may include products with the correct
ingredients or with the wrong ingredients, without active ingredients, with insufficient active
ingredients, or with fake packaging. 34,35 Counterfeit artesunate, predominantly in Southeast
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Asia, has been directly implicated in numerous deaths. 33,36 Travelers to developing countries
should be discouraged from acquiring artesunate while overseas due to the high risk of receiving
a counterfeit medicine. If medicines to treat malaria will likely be needed, it is preferable to fill a
prescription for a reliable supply at a pharmacy in the industrialized country prior to traveling.
Dosage and Administration
Per its IND protocol, artesunate for the treatment of severe malaria should be
administered intravenously at a dose of 2.4 mg/kg initially and then repeated at 12, 24, and 48
hours later for a total of four doses.7 It is worth noting that this dosing regimen is the same as
that used in SEAQUAMAT.23 After three days of therapy, the patient should be switched to an
oral antimalarial agent to ensure a curative treatment.
Summary
For years, IV quinidine has been the sole drug in the United States for the treatment of
severe malaria. However, its limited availability and the need for continuous cardiac monitoring
underscore the need for additional options. The artemisinin class of medications is available
worldwide, has been effective for the treatment of severe malaria, yet is not routinely available in
the United States. Intravenously administered arartesunate is therefore necessary to provide
another treatment option for severe malaria in light of the limitations with the use of quinidine.
Since artesuante is distributed only by the CDC, an FDA-approved, commercially available
formulation with widespread availability would be a welcome addition to the U.S. antimalarial
formulary.
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Table 1: Selected Comparative Treatment Studies
Trial (Year) and

Participants

Interventions

Outcomes measured

Reference
Hien (1992)19

Key results for IV
artesunate

Severe

Artesunate 60mg IV at 0,

malaria

4, 24, and 48 hrs (n=31)

(n=79)




Artemisinin suppositories
600mg initially and at 4



Fever clearance



Fever clearance

time

time faster than

Parasite clearance

quinine (39 vs. 78

time of 50%

hrs)

Mortality



Faster parasite

hrs, then 400mg at 24,

clearance than

32, 48, and 56 hrs (n=18)

quinine (5.4 vs.
16.6 hrs)

Quinine 500mg IV over 4



16.5% mortality

hrs then 500mg IV Q8H

vs. 26.7% for

until able to swallow then

quinine

500mg PO Q8H until day
14 (n=30)
Phuong (1997)22

Age < 15

Artemisinin suppositories 

Mortality

years old

40mg/kg initially then

Number that

with severe

20mg/kg at 4, 24, 48, and

survived with

malaria

72 hrs. (n=37)

neurological

time similar for

sequelae

artesunate and

Fever clearance

quinine (84% and



(n=109)
Artesunate 3mg/kg IM at





11% mortality vs.
14% for quinine



Fever clearance
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Trial (Year) and

Participants

Interventions

Outcomes measured

Reference

Key results for IV
artesunate

0 then 2mg/kg IM at 12,

time

81%)



Resolution of coma



Parasite clearance

time of 5.7 hrs for

Quinine 20mg/kg IV at 0

time of 50%

artesunate vs. 13.2

then 10mg/kg IV Q8H up 

Hypoglycemia

for quinine

24, 48, and 72 hrs (n=37)

to day 7 (n=35)





Parasite clearance

16%
hypoglycemia vs
26% for quinine

Newton (2003)21

Age > 15

Artesunate 2.4mg/kg IV

years old

at 0 then 1.2mg/kg at 12

with severe

and at every 24 hrs until

malaria

able to swallow then

(n=113)

12mg/kg PO Q24H over







7 days (n=59)

Fever clearance



Mean parasitic

time

clearance time of

Parasite clearance

62.5 hrs for

time of 50%

artesunate and 76

Time to regain full

hrs for quinine

conscious



10.2 %



Death

hypoglycemia in

Quinine 20mg/kg over 4



Hypoglycemia

artesunate group

hrs followed by 10mg



Adverse effects

vs. 28% in the

over 2 hrs infused three
times daily until able to
swallow (n=54)

quinine group


Reduced mortality
in artesunate

Page 20 of 28

Trial (Year) and

Participants

Interventions

Outcomes measured

Reference

Key results for IV
artesunate
group vs quinine
group(12% vs
22%)

Mohanty (2004)20 Pediatric

Artesunate 2.4mg/kg IV

cases with

at 0 then 1.2mg/kg at 6

severe

hrs; then every 24 hrs for

malaria

5 days (n=40)

(n=80)






Quinine 20mg/kg IV at 0,
then 10mg/kg IV Q8H



Fever clearance



Time to regain full

time

consciousness was

Parasite clearance

50 hrs in

time of 50%

artesunate group

Time to regain full

vs 70 hrs for

consciousness

quinine

Death



Fever clearance

until able to swallow then

time of 43.5 hrs

10mg/kg PO Q8H until

for artesunate and

day 7 (n=40)

62 hrs for qunine


Parasitic clearance
time of 42 hrs for
artesunate and 52
hrs for qunine



12.5% mortality in
artesunate group,
20% mortality in
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Trial (Year) and

Participants

Interventions

Outcomes measured

Reference

Key results for IV
artesunate
quinine group

Dondorp

Individuals >

Artesunate 2.4mg/kg IV



In hospital death

(SEAQUAMAT)

2 years old

at 0, 12, and 24 hrs then



Death within 48 hrs

15% in artesunate

(2005)23

with severe

2.4mg/kg IV Q24H until



Death after 48 hrs

group, 22% in

malaria

able to swallow then



Neurological

quinine group

(n=1461)

2mg/kg PO until day 7
(n=730)

sequelae





In hospital death

Death after 48 hrs



Time to discharge

was 6% in the



Hypoglycemia

artesunate group

Quinine 20mg/kg infused

and 12% for the

over 4 hours followed by

quinine group

10mg/kg over 2 to 8
hours three times daily
(n=731)
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Table 2: Qualifications to receive intravenous artesunate per investigational new drug protocola, b
Category
Clinical and Laboratory

Eligibility Criteria


Diagnosis of P. falciparum or other Plasmodium species by
microscopy



Strong clinical suspicion of severe malaria without a timely
and reliable microscopic diagnosis

Parenteral Therapy



Inability to take oral medications

Required



High density parasitemia of > 5%



Severe malaria

IV Artesunate Preferred 


IV artesunate more readily available than IV quinidine
Quinidine failure documented as parasitemia of > 10% of
baseline at 48 hours after initiation



Quinidine intolerance defined as
o QRS widening by ≥ 50%
o QT interval > 0.6 seconds
o QTc interval prolonged by >25% of baseline
o Persistent hypotension despite IV fluids
o Development of quinidine ADR



Contraindication to quinidine defined as
o Allergy to quinidine or cinchona alkaloids
o Thrombocytopenic purpura with previous therapy
o AV junctional or idioventricular pacemaker (with

Page 23 of 28

Category

Eligibility Criteria
no atrial activity)
o AV block
o Left bundle branch block or other intraventricular
conduction defects
o Digitalis toxicity
o Myasthenia gravis

Adapted from reference 7
a. Patients must meet at least one eligibility criteria from each category to qualify for IV
artesunate therapy
b. To obtain IV artesunate, the treating physician must first call the CDC Malaria Hotline
at 770-488-7788 (open from 9:00am to 5:00pm eastern time) to determine patient
eligibility. After hours, clinicians may call 770-488-7100 and request to speak with a
CDC Malaria Branch clinician.
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